Affectis Pharmaceuticals AG Identifies Novel Target for the Treatment of Unipolar Disorder

May 15, 2006 – News Release
Munich, Germany – Affectis Pharmaceuticals AG, a biopharmaceutical company developing novel drugs against depression and schizophrenia, announced today that it has identified a genetic variation associated with major depressive disorder. As the variation may have consequences for the functioning of a receptor protein in the brain, it constitutes a promising target for the development of novel anti-depressants. more...

Download German version


back to latest News 2006